Embodiments of the invention are directed to administering a therapeutically effective amount of a purinergic P2 receptor agonist alone or in combination with adenosine receptor antagonist and/or other anti-cancer therapies for the treatment of cancer. Agonist for the P2 receptors include non-hydrolysable ATP analogs. In particular aspects the cancer is a metastatic cancer, such as a bone metastasis.
